Financial Data and Key Metrics Changes - The company reported a cash balance of $39 million against an outstanding debt level of $25 million, providing a $14 million cash cushion above the required $4.6 million [6][16] - Positive net income of $5.2 million was achieved in Q4 2025, marking a $39.8 million improvement from a net loss of $34.6 million in Q4 2024 [9][34] - Adjusted EBITDA for Q4 2025 was $12.9 million, a 48% increase from $8.7 million in Q4 2024, marking the ninth consecutive quarter of positive adjusted EBITDA [9][34] Business Line Data and Key Metrics Changes - Digital revenue decreased 5.8% sequentially to $34.3 million and 31.9% year-over-year, reflecting continued pressure on digital subscriptions [30] - Nutrition and other revenue decreased 9.6% from the prior quarter to $21.2 million and fell 39% year-over-year, although nutrition subscriptions increased 14.3% sequentially [31] Market Data and Key Metrics Changes - The company is transitioning from a multi-level marketing model to an omni-channel model, which has impacted revenue comparisons [4][29] - The nutrition supplement category globally is valued at $164 billion, significantly larger than the digital fitness category [11][12] Company Strategy and Development Direction - The company is focusing on a new innovation pipeline, including the launch of the 10 Minute BODi program and the P90X Generation Next program, aimed at reaching a broader audience [10][19] - Plans to enter the retail market for the first time with new nutritional products, including a new 7-serve Shakeology product, are set for Q2 2026 [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial turnaround, achieving positive operating income and net income for the first time since going public in 2021 [28][34] - The company anticipates that Q3 2026 will be the first quarter for clean year-over-year comparisons, as the legacy business model elements will have been phased out [17][37] Other Important Information - The company has secured improved financial covenants with lenders, allowing for greater operational flexibility [5][35] - The transition to a new Shopify e-commerce platform is expected to enhance direct-to-consumer sales [26][68] Q&A Session Questions and Answers Question: What are management's priorities moving forward? - Management emphasized that profitability remains a primary focus while also reallocating marketing spend towards new initiatives [43][44] Question: Any early reads on the P90X launch? - Initial customer response has been positive, with solid uptake within the subscriber base, but it is still early to assess long-term success [47][48] Question: How is the consumer response to the 10 Minute BODi program? - The program has shown strong uptake, with 8% of viewership coming from microdose fitness workouts, indicating a positive trend [56][58] Question: What is the status of retail conversations for nutritional products? - The company is actively engaging with retailers, with initial placements expected in grocery channels, including a significant deal with Sprouts Farmers Market [65][66]

Financial Data and Key Metrics Changes - In Q4 2025, Anika generated total revenue of $30.6 million, flat year-over-year, consistent with revised full-year expectations [16] - For the full year 2025, total revenue was $112.8 million, a decline of 6% compared to the prior year [20] - GAAP gross margin increased to 63% from 56% in the prior year, reflecting higher revenue from international OA pain sales [18] - Total adjusted EBITDA from continuing operations was $4.5 million in Q4, higher than revised guidance [19] - For the full year, adjusted EBITDA was $5.3 million, or approximately 5% of revenue, outperforming the revised outlook of -3% to +3% [22] Business Line Data and Key Metrics Changes - Commercial channel revenue grew 22% in Q4, reaching $13.3 million, driven by strong international execution and Integrity's momentum [16] - International OA pain management revenue increased 28% in Q4 and 12% for the full year, reflecting strong market share gains [8] - Integrity revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of growth [9] - OEM channel revenue declined 12% in Q4 and 17% for the full year, primarily due to pricing pressures [9][17] Market Data and Key Metrics Changes - International OA pain management remained a key contributor, with strong growth across multiple regions [8] - The U.S. OA pain management pricing environment was challenging, impacting OEM revenue [9] Company Strategy and Development Direction - The company has three strategic priorities: revenue growth through the commercial channel, advancing the HA-based innovation pipeline, and improving operational execution [6][7] - Focus on expanding the international OA pain portfolio and scaling Integrity as a differentiated regenerative platform [6] - The company aims to strengthen operational execution through improved manufacturing and a streamlined organizational design [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver improved performance and long-term value, entering 2026 with clarity and momentum [28] - The company anticipates total revenue for 2026 to be between $114 million and $122.5 million, reflecting continued momentum in the commercial channel [26] - Adjusted EBITDA for 2026 is expected to be 5%-10% of revenue, supported by commercial channel growth and cost reduction actions [27] Other Important Information - The company ended 2025 with $57.5 million in cash and no debt, providing a strong liquidity position [23] - A $15 million stock repurchase plan was initiated in November 2025, with $10.7 million already purchased [24] Q&A Session Summary Question: Contribution from Hyalofast in 2027 - Management confirmed that approximately $3 million of anticipated revenue for Hyalofast in 2027 remains unchanged, contingent upon U.S. approval [30] Question: Normalized gross margin expectations - Management indicated that a normalized gross margin in the high 50s is appropriate for future planning [31] Question: Future free cash flow expectations - Management expects free cash flow in 2026 to be somewhat in line with 2025 results [35] Question: International OA pain market dynamics - Management noted sustained market share gains and growth in new markets, with no single market driving top-line growth [36] Question: OEM channel sequential improvement - Management attributed the sequential improvement to volume and end-user demand, with continued conversations with J&J regarding future market dynamics [40] Question: Timeline for Cingal's NDA filing - Management stated that the NDA filing timeline will depend on the enrollment of the bioequivalence study, which is currently ongoing [43] Question: Integrity's revenue growth expectations - Management expects strong double-digit growth for Integrity in 2026, although not at the same percentage increase as in 2025 [44] Question: Capital allocation priorities - Management emphasized that capital allocation will focus on manufacturing improvements and investments in the U.S. sales channel, with potential for future evaluations of M&A opportunities [53]

Financial Data and Key Metrics Changes - In Q4 2025, Anika generated total revenue of $30.6 million, flat year-over-year, with commercial channel revenue growing 22% to $13.3 million [18][19] - For the full year 2025, total revenue was $112.8 million, a decline of 6% compared to the prior year, while commercial channel revenue increased by 15% to $48.4 million [23][24] - GAAP gross margin improved to 63% in Q4 2025 from 56% in the prior year, while full-year gross margin was 57%, down from 63% in 2024 [20][24] Business Line Data and Key Metrics Changes - The international OA pain management business delivered 28% growth in Q4 2025, contributing significantly to the commercial channel's performance [9][19] - Integrity revenue more than doubled to approximately $6 million in 2025, marking its seventh consecutive quarter of growth [10][23] - OEM channel revenue declined 12% in Q4 and 17% for the full year, primarily due to pricing pressures [10][24] Market Data and Key Metrics Changes - International OA pain revenue increased 28% in Q4 and 12% for the full year, reflecting strong execution and market share gains [9][19] - The OEM channel faced challenges with a decline in revenue, attributed to a more challenging pricing environment in the U.S. [10][24] Company Strategy and Development Direction - The company has three strategic priorities: revenue growth through the commercial channel, advancing the HA-based innovation pipeline, and improving operational execution [6][8] - Focus on expanding the international OA pain portfolio and scaling Integrity as a differentiated regenerative platform [6][7] - The company aims to enhance manufacturing productivity and streamline operations to improve profitability and cash generation [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver improved performance and long-term value, entering 2026 with clarity and momentum [30][31] - The outlook for 2026 includes total revenue guidance of $114 million to $122.5 million, reflecting continued growth in the commercial channel [28][30] Other Important Information - The company generated $11.2 million in operating cash flow for 2025, an improvement over the previous year, and ended the year with $57.5 million in cash and no debt [26] - A $15 million stock repurchase plan was initiated in November 2025, with $10.7 million already purchased [26] Q&A Session Summary Question: Contribution from Hyalofast in 2027 - Management confirmed that approximately $3 million of anticipated revenue for Hyalofast in 2027 remains unchanged, contingent upon U.S. approval [34] Question: Normalized gross margin expectations - Management indicated that a normalized gross margin should be in the high 50s, acknowledging that the current quarter's margin is not sustainable in the near term [35][36] Question: Future free cash flow expectations - Management expects free cash flow in 2026 to be somewhat in line with 2025 levels, considering restructuring-related elements [37][39] Question: International OA pain dynamics - Management noted sustained market share gains and growth in new markets, with no single market driving top-line growth [40][41] Question: OEM channel sequential improvement - Management attributed the sequential improvement in the OEM channel to volume and end-user demand, with expectations for continued market share gains [44] Question: Timeline for Cingal's NDA filing - Management stated that the NDA filing timeline will depend on the enrollment of the bioequivalence study, which is currently ongoing [46] Question: Integrity's revenue growth in 2026 - Management expects strong double-digit growth for Integrity in 2026, although not at the same percentage increase as in 2025 [48] Question: Capital allocation priorities - Management emphasized that capital allocation focuses on delivering for patients and customers, with investments in manufacturing and U.S. sales channels being top priorities [57][59]

Core Insights - Fiscal 2025 was challenging, but decisive actions have positioned the company for future growth, with first quarter net sales and adjusted EBITDA exceeding expectations despite ongoing headwinds [1][2] - The company is optimistic about the recovery in consumables, particularly in the global pet care business, which has returned to growth [4][44] - The overall financial results indicate that the company is on track to achieve its growth objectives for fiscal 2026, with expectations for net sales and adjusted EBITDA to show improvement [40][46] Financial Performance - First quarter net sales decreased by 3.3%, with organic net sales down 6%, primarily due to softness in the home and personal care business [16] - Adjusted EBITDA for the quarter was $62.6 million, a decrease of $15.2 million driven by lower volume and reduced gross margins [18] - The company generated nearly $660 million of adjusted free cash flow in the first quarter and repurchased approximately 600,000 shares [5][6] Business Unit Performance - The global pet care business reported an 8.3% increase in net sales, with organic net sales up 5.8%, driven by strong performance in companion animal categories [20][21] - Home and garden business net sales decreased by 19.8%, but the company expects sales to pick up as the season unfolds, with early indications of strong POS trends [27][29] - Home and personal care business saw a reported net sales decrease of 7.6%, with organic net sales down 11.1%, but there are signs of recovery in core markets [32][34] Strategic Initiatives - The company is focused on maintaining a healthy balance sheet and optimizing working capital, ending the first quarter with nearly $127 million in cash and a net leverage of 1.65 turns [9][12] - Strategic priorities for fiscal 2026 include investing in people, operational excellence, and transformation, with a focus on fewer, bigger, better initiatives [7][11] - The company is committed to disciplined expense management and is optimistic about the evolving M&A landscape, particularly in the global pet care and home and garden sectors [46][44] Market Outlook - The company expects net sales growth in the home and garden business to occur in the second half of the fiscal year, with anticipated improvements in consumer demand [41][39] - Adjusted EBITDA is expected to grow in low single digits, driven by the return to sales growth in the global pet care and home and garden businesses [40][46] - The company remains cautious about the home and personal care business, expecting continued softness in consumer demand in the near term [39][57]

Financial Data and Key Metrics Changes - In Q1 2026, net sales decreased by 3.3%, with organic net sales down 6% primarily due to softness in the Home and Personal Care business and an accelerated seasonal inventory build from the previous year [17] - Adjusted EBITDA for the quarter was $62.6 million, a decrease of $15.2 million, driven by lower volume and reduced gross margins [19] - Gross profit decreased by $16.2 million, with a gross margin of 35.7%, down 110 basis points [18] Business Line Data and Key Metrics Changes - Global Pet Care reported net sales increased by 8.3%, with organic net sales up 5.8%, driven by strong performance in companion animal and aquatics categories [21] - Home and Garden net sales decreased by 19.8%, aligning with historical averages for the first quarter, which is typically the slowest sales quarter [26] - Home and Personal Care saw reported net sales decrease by 7.6%, with organic net sales down 11.1%, impacted by higher inventory levels at a retailer following a weaker holiday season [31] Market Data and Key Metrics Changes - North America showed growth in the Global Pet Care segment, with sales increasing in both companion animal and aquatics [21] - EMEA sales in Global Pet Care decreased in the low single digits, primarily due to a decline in dog and cat food sales following a portfolio refresh [22] - LATAM region experienced high teens growth in Home and Personal Care, driven by positive consumer reactions to new product launches [32] Company Strategy and Development Direction - The company aims to maintain a healthy balance sheet and focus on operational excellence, with a disciplined approach to investments and a commitment to innovation [10][12] - The strategic priority includes transformation, with expectations for both Global Pet Care and Home and Garden businesses to return to growth in fiscal 2026 [13][15] - The company is optimistic about the evolving M&A landscape and aims to be a consolidator of choice in its categories [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the most significant impacts from tariff disruptions and macroeconomic volatility are largely behind them, with early signs of recovery in consumables [5] - The company anticipates continued softness in global consumer demand within Home and Personal Care categories, with expectations for improvement in the second half of the fiscal year [37] - Management reiterated expectations for flat to low single-digit growth in net sales and low single-digit growth in Adjusted EBITDA for fiscal 2026 [45] Other Important Information - The company generated nearly $60 million of adjusted free cash flow in Q1 and repurchased approximately 600,000 shares [8] - A new $300 million share repurchase program has been authorized by the board [8] - The company ended the quarter with a cash balance of $126.6 million and $492.2 million available on its cash flow revolver [20] Q&A Session Questions and Answers Question: Do you agree with a competitor's assessment that the pet market has reached a bottom? - Management refrained from making predictions about market bottoms but expressed satisfaction with the new leadership and market share gains in the pet segment [48][49] Question: How committed are retailers to the garden category this upcoming season? - Management expressed bullishness on the Home and Garden business, citing strong POS trends and successful new product launches [50][51] Question: Can you discuss the anticipated improvement in sales growth for the year? - Management indicated that while the pet business is expected to continue growing, Home and Garden may see a more back-half weighted growth story due to disciplined inventory management by retailers [56][58] Question: Are investment levels in brands where you want them? - Management stated that investment levels are appropriate for Global Pet Care and Home and Garden, but there may be a pullback in Home and Personal Care investments based on recovery timing [62][64] Question: Can you elaborate on the innovation pipeline for FY 2026? - Management confirmed a strong pipeline of new products for both Home and Garden and Global Pet Care, with plans for expanded distribution [66]

Core Viewpoint - Zomedica is focusing on its R&D strategy to support scalable growth and enhance long-term shareholder value through an upcoming investor webinar [1] Group 1 - The company is an animal health firm that provides innovative diagnostic and therapeutic devices for both equine and companion animals [1] - The next installment of the "Fourth Friday at Four" investor webinar series is scheduled for February 27, 2026, at 4:00 p.m. Eastern Time [1]

Core Insights - Crocs, Inc. is focusing on innovation to regain momentum in a challenging demand environment, emphasizing product expansion and partnerships to enhance consumer excitement and brand relevance [2][3][5] Financial Performance - The third-quarter fiscal 2025 results exceeded expectations but did not meet the company's internal benchmarks, prompting a renewed focus on product innovation and brand management [3] - The Zacks Consensus Estimate for fiscal 2025 earnings indicates a year-over-year decline of 7.9%, while fiscal 2026 shows a projected growth of 3.9% [11] Product Strategy - Crocs is expanding its product lines, including new Clog franchises like the Crafted Clog and the Echo franchise, which includes successful products like Echo RO and Echo 2.0 [3][9] - The sandals segment outperformed the overall portfolio, gaining market share with strong demand for products like Brooklyn, Gataway, and Miami [4][9] Marketing and Engagement - Collaborations with influencers, such as the Cozzzy "Unfurgettable" line with Millie Bobby Brown, have driven significant social media engagement and product growth [4][9] - The company is leveraging digital strategies, particularly on platforms like TikTok, to enhance global engagement and support long-term growth [5] Valuation Metrics - Crocs shares have declined by 33% year-to-date, compared to an 18.9% decline in the industry, with a Zacks Rank of 1 (Strong Buy) [6] - The forward price-to-earnings ratio for Crocs is 5.85X, significantly lower than the industry average of 15.79X, indicating potential undervaluation [7]

Summary of Artivion Conference Call Company Overview - **Company**: Artivion - **Industry**: Medical Devices, specifically focusing on aortic technologies Key Points and Arguments Strategic Focus and Vision - Artivion has shifted its focus to cardiac and vascular surgeons treating the aorta, divesting non-aortic products to concentrate on unmet clinical needs in this area [2][3][5] - The company has made several strategic acquisitions over the past five years, including On-X, Jotec, and Ascyrus, to enhance its product offerings and address significant clinical challenges [3][5][6] Product Pipeline and Growth - Artivion has a robust pipeline with seven PMAs (Premarket Approvals) in progress, indicating a strong future growth trajectory without the immediate need for further acquisitions [9][10] - The company anticipates double-digit revenue growth and EBITDA growth at twice the rate of revenue for many years, with recent quarters showing even higher growth rates [15][17][40] AMDS Technology - The AMDS (Aortic Malperfusion Device System) is expected to expand the market for treating acute type A aortic dissections, potentially reducing mortality rates significantly [18][20] - AMDS is positioned to be used in a wider range of centers, which could lead to increased adoption and market expansion [18][20][21] Competitive Landscape - AMDS competes with existing technologies like the Frozen Elephant Trunk and hemianchor repair, but its ease of use and effectiveness may lead to broader adoption among surgeons [21][23] - The company aims to maintain a comprehensive aortic strategy by offering multiple treatment options, ensuring they meet diverse patient needs [23][24] Financial Performance and Projections - The mechanical heart valve business, particularly On-X, has seen significant growth, with recent quarters showing over 20% growth, driven by new clinical data demonstrating advantages over bioprosthetic valves [28][30][31] - The company expects gross margins to improve, with a target of reaching 70% in the long term, driven by the introduction of high-margin products [42][45] Operational and Financial Management - Artivion is focused on maintaining operational scalability to support growth, ensuring that infrastructure keeps pace with increasing demand for high-margin products [49][50] - The company has a solid cash flow management strategy, with priorities including funding for potential acquisitions and debt repayment [57] Market Dynamics and Reimbursement - The introduction of a new DRG (Diagnosis-Related Group) for complex aortic arch procedures is expected to facilitate AMDS adoption by improving reimbursement rates [27] - The company has successfully navigated previous reimbursement challenges, and the new DRG is seen as a positive development for market entry [27] Future Outlook - Artivion is optimistic about its growth prospects, with plans to train surgeons on AMDS and leverage new clinical data to drive market share [33][36] - The company is committed to a long-term growth strategy, focusing on innovation and customer needs in the aortic space [60][61] Additional Important Insights - The company has experienced a significant shift in its market positioning and is now seen as a leader in aortic technologies, with a clear focus on addressing critical clinical needs [1][2][60] - Artivion's management emphasizes the importance of aligning all teams towards a common goal of delivering innovative aortic solutions to improve patient outcomes [60][61]

Financial Data and Key Metrics Changes - The company achieved net income of $3.6 million in Q3 2025, marking its first net income since going public in 2021, compared to a net loss of $12 million in the prior year [23] - Adjusted EBITDA was $9.5 million, up from $4.6 million in the prior quarter and down from $10.1 million in the prior year [23] - Total revenues were $59.9 million, a decline of 6.3% sequentially and 41.4% year over year, aligning with expectations due to the strategic transition [18] - Gross margins improved to 74.6%, an increase of 230 basis points from the prior quarter and 730 basis points year over year [19] Business Line Data and Key Metrics Changes - Digital revenue decreased 8.3% from the prior quarter to $36.4 million and decreased 32.2% year over year, impacted by a decline in digital subscription counts [19] - Nutrition and other revenue decreased 2.8% from the prior quarter to $23.5 million and fell 50.4% year over year, with nutrition subscriptions remaining flat sequentially at approximately 70,000 [20] Market Data and Key Metrics Changes - The company is transitioning from a multi-level marketing (MLM) model to an omnichannel approach, which has impacted revenue streams and customer acquisition strategies [18][19] - The shift has opened new growth channels that were previously inaccessible, with expectations for a stronger balance sheet and long-term business model [25] Company Strategy and Development Direction - The company plans to launch a comprehensive retail initiative in 2026, introducing products like Shakeology and new nutritional supplements to retail for the first time [5][6] - A new P90X fitness program will be launched, creating cross-marketing opportunities between digital content and retail nutrition products [6] - The focus will be on expanding the total addressable market (TAM) by targeting the 185 million overweight Americans who do not currently engage in regular fitness routines [6][14] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the turnaround progress, achieving eight consecutive quarters of positive adjusted EBITDA and a significant reduction in the revenue break-even point from $900 million to $180 million [4][7] - The company anticipates that 2026 will mark the transition from financial restructuring to capitalizing on new revenue opportunities [5][15] - Management highlighted the importance of leveraging AI and technology to enhance customer experience and drive acquisition [15][16] Other Important Information - The company has generated $13.1 million in free cash flow year-to-date, with $9 million generated in Q3 alone [4] - The cash position stands at $33.9 million, exceeding outstanding debt of $25 million, providing financial flexibility [4] Q&A Session Summary Question: Changes in Customer Base with New Business Model - Management noted that the customer demographic remains similar, focusing on individuals seeking convenience and shorter workout durations [32] Question: New Product Pipeline and Rollout Timing - The company is excited about launching numerous new products in 2026, including affordable nutrition products and fitness programs [38][39] Question: Marketing Spend and Cost Management - Management confirmed that marketing spend is aligned with the new business model, maintaining operational leverage while managing costs effectively [41][62] Question: Retail Launch Visibility - The company is currently coordinating sell-in meetings with major retailers, expecting to appear on shelves by late Q1 to Q2 2026 [59] Question: Nutrition Margin Expectations - Management anticipates a steady state for nutrition margins between 46-52%, with a focus on generating revenue and subscriber growth [74]

Financial Data and Key Metrics Changes - The company reported record quarterly net sales of $2.2 billion for Q3 2025, a 16.8% increase from $1.88 billion in Q3 2024 [12] - Gross profit as a percentage of net sales increased to 55.7% in Q3 2025 from 53.2% in Q3 2024, driven by pricing actions and supply chain optimization [14] - Operating income rose 40.7% to $675.4 million in Q3 2025 from $479.9 million in Q3 2024 [17] - Net income per diluted share increased 41.1% to $0.53 from $0.38 in the same quarter last year [17] Business Line Data and Key Metrics Changes - Net sales for the Monster Energy Drink segment increased 17.7% to $2.03 billion in Q3 2025 from $1.72 billion in Q3 2024 [13] - The Strategic Brand segment saw a 15.9% increase in net sales to $130.5 million in Q3 2025 [13] - The alcohol brand segment experienced a 17% decrease in net sales to $33 million in Q3 2025 from $39.8 million in Q3 2024 [13] Market Data and Key Metrics Changes - Net sales to customers outside the U.S. rose to approximately 43% of total reported net sales in Q3 2025, the highest percentage recorded by the company for a single quarter [9] - In EMEA, net sales increased by 30.3% in dollars and 23.0% on a currency-neutral basis [22] - In APAC, net sales increased 28.7% in dollars and 26.9% on a currency-neutral basis [24] Company Strategy and Development Direction - The company continues to focus on innovation, with a robust pipeline planned for 2026, including new product launches and limited-time offerings [20][21] - Marketing efforts are aimed at growing the core business and attracting new consumers, with significant sponsorships and events enhancing brand exposure [10] - The company is implementing pricing adjustments to optimize revenue growth while maintaining minimal impact on volume [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term prospects for the energy drink category, citing increasing household penetration and consumer demand for energy [32] - The company anticipates a modest impact from tariffs in the upcoming quarters but does not expect them to materially affect operating results [11] - Management highlighted the importance of brand image and functionality in driving category growth, particularly in EMEA [36] Other Important Information - The company has approximately $500 million remaining for stock repurchase under its authorized program as of November 5, 2025 [29] - October 2025 sales are estimated to be approximately 14.1% higher than October 2024 sales on a non-foreign currency-adjusted basis [30] Q&A Session Summary Question: What is driving the strong category growth in Western Europe compared to the U.S.? - Management attributed the growth to a strong value proposition, brand image, and functionality of energy drinks, with a significant portion of new consumers coming from other beverage categories [35][36] Question: How does the company see category growth evolving into 2026? - Management noted that while they do not provide guidance, key drivers include the value proposition of energy drinks and increasing household penetration [40][41] Question: What level of pricing is expected from the recent adjustments? - Management indicated that the pricing adjustments are strategic and aimed at optimizing revenue without significantly impacting volumes [44] Question: What contributed to the strong gross margins in the quarter? - The increase in gross margins was attributed to positive pricing actions, supply chain optimization, and a favorable product sales mix [46][47] Question: How will affordable energy products impact international margins? - Management believes that affordable energy products will positively contribute to overall margins internationally, although not significantly [50]